Elevation of FVIII: C in Venous Thromboembolism Is Persistent and Independent of the Acute Phase Response

Summary

Recent literature has suggested a role for elevated FVIII:C in venous thromboembolic disease (VTED). However since FVIII:C is known to rise in response to an acute phase reaction, it is difficult to determine whether the increased FVIII:C precedes the thrombosis or represents a secondary reactive phenomenon. In an attempt to address this question, we followed 35 patients with confirmed VTED, raised FVIII:C level (>1.5 iu/ml) and no other thrombotic tendency. Serial measurements of FVIII:C, vWF:Ag, C-reactive protein and fibrinogen were performed. We hypothesized that a persistent increase in FVIII:C in the absence of any other measures of ongoing acute phase response, would support the idea that elevation of FVIII:C is a constitutional phenomenon.

Of this initial group, 94% continued to have an elevated FVIII:C level throughout the period of follow up (median 8 months; range 3 to 39 months), with no significant difference between the FVIII:C levels determined at first estimation and those obtained during follow up (p = 0.58). Conversely, only 18% had evidence of an acute phase reaction when first assessed, and nonparametric ranking analysis demonstrated no correlation between FVIII:C and either C-reactive protein or fibrinogen (p = 0.315 and 0.425 respectively).We conclude that increased FVIII:C levels following VTED are persistent, independent of the acute phase reaction, and thus may represent a constitutional risk factor for VTED.

Keywords

FVIII:C - venous thromboembolism - acute phase

• References

• 1 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 2 O’Donnell J, Tuddenham EGD, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
• 3 Kraaijenhagen RA, Anker PS, Koopman MMW, Reitsma P, Prins M, Buller HR. High plasma concentration of factor VIII:C: a major risk factor for venous thromboembolism. Blood 1998; (Suppl. 01) 501.
• 4 Orstavik K, Magnus P, Reisner H, Berg K, Graham J, Nance W. Factor VIII and Factor IX in a Twin Population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89-101.
• 5 Preston AE, Barr A. The plasma concentration of factor VIII in the normal population. Brit J Haemat 1964; 10: 238-45.
• 6 Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
• 7 McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983; 03: 757.
• 8 Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan A, Das KC. Major blood group antigens – a determinant factor of factor VIII levels in blood. Thromb Haemost 1984; 51: 414.
• 9 Sodetz J, Paulson J, McKee P. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human factor VIII/von Willebrand factor. J Biol Chem 1979; 254: 10754-60.
• 10 Matsui T, Titani K, Mizuochi T. Structures of the asparaginase-linked oligosaccharide chains of human von Willebrand factor. J Biol Chem 1992; 267: 8723-31.
• 11 Kingsbury KJ. Relation of ABO blood-groups to atherosclerosis. Lancet 1971; i: 199-203.
• 12 Talbot S, Wakely EJ, Ryrie D, Langman MJS. ABO blood groups and venous thromboembolic disease. Lancet 1970; i: 1257-9.
• 13 Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haem 1994; 88: 601-7.
• 14 Nichols W, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatlet MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsberg D. Mutations in the ER-Golgi Intermediate Compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93: 61-70.
• 15 Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, De Fair U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
• 16 Smith FB, Lane GDO, Fowkes FG, Rumley A, Rumley AG, Donnan PT, Housley E. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral artery disease. Atherosclerosis 1993; 102: 155-62.
• 17 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabati RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
• 18 O’Brien JR. Blood group, von Willebrand’s factor and heart disease. Thromb Res 1990; 59: 221.
• 19 Kamphuisen PW, Eikenboom JCJ, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of Factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
• 20 Pottinger BE, Read RC, Paleolog EM, Pearson JD. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 389.